Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites

被引:5
作者
Argyropoulos, Kimon [1 ,2 ]
Basu, Atreyee [1 ,3 ]
Park, Kyung [1 ]
Zhou, Fang [1 ]
Moreira, Andre L. [1 ]
Narula, Navneet [1 ]
机构
[1] New York Univ Langone Hlth, Dept Pathol, New York, NY 10016 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Tufts Med Ctr, Boston, MA USA
关键词
adenocarcinoma; grade; histology; lung; molecular; PD-L1; PD-L1; EXPRESSION; PROTEIN EXPRESSION; GRADING SYSTEM; CANCER; PEMBROLIZUMAB; HETEROGENEITY; MULTICENTER; PREVALENCE; MUTATIONS; OUTCOMES;
D O I
10.1016/j.modpat.2023.100245
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Programmed death-ligand 1 (PD-L1) expression in terms of the tumor proportion score (TPS) is the main predictive biomarker approved for immunotherapy against lung nonsmall cell carcinoma. Although some studies have explored the associations between histology and PD-L1 expression in pulmonary adenocarcinoma, they have been limited in sample size and/or extent of examined histologic variables, which may have resulted in conflicting information. In this observational retrospective study, we identified primary and metastatic lung adenocarcinoma cases in the span of 5 years and tabulated the detailed histopathologic features, including pathological stage, tumor growth pattern, tumor grade, lymphovascular and pleural invasion, molecular alterations, and the associated PD-L1 expression for each case. Statistical analyses were performed to detect associations between PD-L1 and these features. Among 1658 cases, 643 were primary tumor resections, 751 were primary tumor biopsies, and 264 were metastatic site biopsies or resections. Higher TPS significantly correlated with high-grade growth patterns, grade 3 tumors, higher T and N stage, presence of lymphovascular invasion, and presence of MET and TP53 alterations, whereas lower TPS correlated with lower-grade tumors and presence of EGFR alterations. There was no difference in PD-L1 expression in matched primary and metastases, although higher TPS was observed in metastatic tumors due to the presence of high-grade patterns in these specimens. TPS showed a strong association with a histologic pattern. Higher-grade tumors had higher TPS, which is also associated with more aggressive histologic features. Tumor grade should be kept in mind when selecting cases and blocks for PD-L1 testing.& COPY; 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 30 条
[1]   Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].
Aguilar, E. J. ;
Ricciuti, B. ;
Gainor, J. F. ;
Kehl, K. L. ;
Kravets, S. ;
Dahlberg, S. ;
Nishino, M. ;
Sholl, L. M. ;
Adeni, A. ;
Subegdjo, S. ;
Khosrowjerdi, S. ;
Peterson, R. M. ;
Digumarthy, S. ;
Liu, C. ;
Sauter, J. ;
Rizvi, H. ;
Arbour, K. C. ;
Carter, B. W. ;
Heymach, J. V. ;
Altan, M. ;
Hellmann, M. D. ;
Awad, M. M. .
ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659
[2]   Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses [J].
Basu, Atreyee ;
Chiriboga, Luis ;
Narula, Navneet ;
Zhou, Fang ;
Moreira, Andre L. .
JOURNAL OF HISTOTECHNOLOGY, 2020, 43 (04) :174-181
[3]   Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression [J].
Cai, Yiran ;
Wu, Hongbo ;
Shi, Xiaoqin ;
Dong, Yujie ;
Chang, Xiujun ;
Zhang, Li ;
Zhou, Lijuan ;
Su, Dan ;
Yang, Ming .
BMC CANCER, 2020, 20 (01)
[4]   Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status [J].
Cha, Yoon Jin ;
Kim, Hye Ryun ;
Lee, Chang Young ;
Cho, Byoung Chul ;
Shim, Hyo Sup .
LUNG CANCER, 2016, 97 :73-80
[5]   Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma [J].
Da Cruz, Vanessa ;
Yvorel, Violaine ;
Casteillo, Francois ;
Tissot, Claire ;
Luchez, Antoine ;
Bayle-Bleuez, Sophie ;
Fournel, Pierre ;
Tiffet, Olivier ;
Peoc'h, Michel ;
Forest, Fabien .
LUNG CANCER, 2020, 147 :77-82
[6]   Microsatellite Instability Is Rare in the Admixed Brazilian Population of Non-Small Cell Lung Cancer: A Cohort of 526 Cases [J].
De Marchi, Pedro ;
Berardinelli, Gustavo Noriz ;
Cavagna, Rodrigo de Oliveira ;
Pinto, Icaro Alves ;
Ferreira da Silva, Flavio Augusto ;
da Silva, Vinicius Duval ;
Vidigal Santana, Iara Viana ;
Albino da Silva, Eduardo Caetano ;
Leal, Leticia Ferro ;
Reis, Rui Manuel .
PATHOBIOLOGY, 2022, 89 (02) :101-106
[7]   Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non small-cell lung cancer: The global, multicenter EXPRESS study [J].
Dietel, M. ;
Savelov, N. ;
Salanova, R. ;
Micke, P. ;
Bigras, G. ;
Hida, T. ;
Antunez, J. ;
Skov, B. Guldhammer ;
Hutarew, G. ;
Sua, L. F. ;
Akita, H. ;
Chan, O. S. H. ;
Piperdi, B. ;
Burke, T. ;
Khambata-Ford, S. ;
Deitz, A. C. .
LUNG CANCER, 2019, 134 :174-179
[8]  
Domenech Marta, 2021, Oncotarget, V12, P1802, DOI 10.18632/oncotarget.28045
[9]   Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes [J].
Forest, Fabien ;
Casteillo, Francois ;
Da Cruz, Vanessa ;
Yvorel, Violaine ;
Picot, Tiphanie ;
Vassal, Francois ;
Tiffet, Olivier ;
Peoc'h, Michel .
LUNG CANCER, 2021, 155 :1-9
[10]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092